Vnitr Lek 2009, 55(2):106-110

Impact of body weight on the risk of venous thromboembolism

T. Petrovič*, T. Koller, J. Payer
V. interná klinika Lekárskej fakulty UK a FNsP Bratislava-Ružinov, Slovenská republika, prednosta prof. MUDr. Juraj Payer, CSc.

Introduction:
Obesity and venous thromboembolism represent a serious medical problem.

Material and methods:
Their mutual relationship was studied on the group of 124 patients with venous thromboembolism (the study group) and was compared to the group of 124 randomly chosen controls among hospitalized patients matched for age, sex and risk factor profile of venous thromboembolism (the control group).

Results:
Recorded variables were body weight, presence of arterial hypertension, hypertriglyceridemia and type 2 diabetes or impaired glucose tolerance. We found significantly higher prevalence of obesity - 40 vs 23 patients (38.5% vs 23%, p = 0.0283) and significantly higher BMI (29.254 vs 26.923, p = 0.002) in the study group. Increased body weight was found to be the only significant risk factor for venous thromboembolism (odds ratio = 2.507, p = 0.0026) and normal body weight was the only protective factor (odds ratio = 0.3989, p = 0.0026). We equally found the significant increase of the prevalence of venous thromboembolism with increasing body weight (p = 0.020). Even in patients without known risk factors for venous thromboembolism (n = 55) we found significantly higher prevalence of increased body weight (BMI > 25) in the study group (82.4% vs 61.2%, p = 0.0221). No other recorded variable was significantly more frequent in the study group.

Conclusion:
Reduction of body weight could therefore represent an important challenge in preventing the venous thromboembolism.

Keywords: venous tromboembolism; body weight; metabolic syndrom

Received: April 4, 2008; Accepted: December 1, 2008; Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petrovič T, Koller T, Payer J. Impact of body weight on the risk of venous thromboembolism. Vnitr Lek. 2009;55(2):106-110.
Download citation

References

  1. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32: 269-273. Go to original source... Go to PubMed...
  2. Remková A. Protrombotický stav ako súčasť metabolického syndrómu. Vnitř Lék 2005; 51: 1120-1125.
  3. Remková A. Hypertenzia a hemostáza. Bratislava: Slovak Academic Press 1998.
  4. Giandomenico G, Dellas C, Czekay RP et al. The leptin receptor system of human platelets. J Thromb Haemost 2005; 3: 1042-1049. Go to original source... Go to PubMed...
  5. Hori Y, Gabazza EC, Yano Y et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665. Go to original source... Go to PubMed...
  6. Erem C, Hacihasanoğlu A, Çelik S et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract 2005; 14: 22-30. Go to original source... Go to PubMed...
  7. Aso Y, Wakabayashi S, Yamamoto R et al. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005; 28: 2211-2216. Go to original source... Go to PubMed...
  8. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-1579. Go to original source... Go to PubMed...
  9. Vayá A, Mira Y, Ferrando F et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118: 255-259. Go to original source... Go to PubMed...
  10. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-980. Go to original source... Go to PubMed...
  11. Petrauskiene V, Falk M, Waernbaum I et al. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005; 48: 1017-1021. Go to original source... Go to PubMed...
  12. Tsai AW, Cushman M, Rosamond WD et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189. Go to original source... Go to PubMed...
  13. Lacut K, Oger E, Le Gal G et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004; 18: 477-482. Go to original source... Go to PubMed...
  14. Ageno W, Becattini C, Brighton T et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102. Go to original source... Go to PubMed...
  15. Goldhaber SZ, Grodstein F, Stampfer MJ et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-645. Go to original source...
  16. Ay C, Tengler T, Vormittag R et al. Venous thromboembolism - a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374-380. Go to original source... Go to PubMed...
  17. Ageno W, Prandoni P, Romualdi E et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 4: 1914-1918. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.